Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astegolimab in chronic obstructive pulmonary disease
PACTR202305580698795Phase 3Recruiting
- Sponsor
- Roche
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of astegolimab in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Roche. Primary endpoint: Annualized rate of moderate and severe chronic obstructive pulmonary disease exacerbations. Started Oct 2023; status: recruiting.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on PACTR202305580698795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202305580698795.